modakafusp alfa + daratumumab + pomalidomide

This is a **combination regimen** of three drugs—**modakafusp alfa**, **daratumumab**, and **pomalidomide**—investigated for the treatment of relapsed or refractory multiple myeloma. Modakafusp alfa (TAK-573) is an engineered **CD38-targeting immunocytokine** that delivers interferon-alpha to malignant cells. Daratumumab is a **monoclonal antibody targeting CD38**, exerting direct anti-myeloma activity and engaging immune-mediated mechanisms. Pomalidomide is an **immunomodulatory agent** that affects the tumor microenvironment and has antineoplastic, antiangiogenic, and immunomodulatory actions. The combination exploits **synergistic effects** by using complementary mechanisms against multiple myeloma cells. Developed primarily by Takeda for modakafusp alfa, Janssen (Johnson & Johnson) for daratumumab, and Bristol Myers Squibb for pomalidomide[1][3][5].